Compare Medtronic PLC (MDT) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Medtronic PLC trades at $83.21 (market cap $106.61B), while Global X NASDAQ 100 Covered Call ETF trades at $17.78. The key difference: Medtronic PLC pays a 3.46% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| MDT | QYLD | |
|---|---|---|
Market Cap | $106.61B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $105.35 | $18.52 |
52-Week Low | $73.75 | $16.46 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
QYLD trades at $17.66, down 0.84% with a bearish technical signal from moving averages. The ETF's covered-call strategy generates high income but has underperformed the Nasdaq-100's growth over the long term. Recent dividend payments of $0.18-$0.19 per share continue the fund's income-focused approach while technical indicators show neutral oscillators but bearish momentum signals.
The outlook remains challenging as QYLD's high yield comes at the cost of capital appreciation. While attractive for income-seeking investors, the fund faces structural headwinds in strong bull markets. Key risks include NAV erosion during market rallies and competition from lower-fee alternatives like GPIQ.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
